Jump to start of content

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Test and Policy Committee on Transplant Hepatology

Expand All | Collapse All

Hugo E. Vargas, MD, MS, Chair

Dr. Vargas is Professor of Medicine for the Mayo Clinic College of Medicine, Director of the Office of Clinical Research, and Vice Chair of the Division of Gastroenterology and Hepatology at Mayo Clinic in Scottsdale, Arizona. He specializes in the management of viral hepatitis, complications of portal hypertension, and liver transplantation.

In addition, Dr. Vargas has authored or coauthored more than 125 peer-reviewed articles in journals such as Hepatology, Gastroenterology, American Journal of Transplantation, and New England Journal of Medicine. He is Chair of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology. Dr Vargas is a fellow of the American Association for the Study of Liver Diseases (AASLD), American College of Gastroenterology, American College of Physicians, and American Gastroenterological Association. He also co-chairs the AASLD/Infectious Disease Society of America Hepatitis C Virus treatment guidelines panel. In 2010, he received the Outstanding Program Director of the Year Award from the Mayo Clinic College of Medicine's Department of Education Administration.

He is a graduate of Hahnemann Medical School of Drexel University, and completed his internal medicine residency with University of Utah Affiliated Hospitals and fellowship in gastroenterology and hepatology at the University of Pittsburgh Medical Center.

As of February 2019, Dr. Vargas reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the Mayo Clinic, from the following company:

  • Arrowhead, for a retrospective medical record review study to characterize Alpha-1 Antitrypsin Deficiency -Associated Liver Disease, receiving funding for clinical trial expenses and staff.
  • Mallinckrodt Pharmaceuticals, for a trial for treatment of hepatorenal syndrome, receiving funding for clinical trial expenses, staff and salary support.

Service on data and safety monitoring boards for the following company, with compensation for travel expenses and honoraria:

  • TransMedics, for a graft preservation device in liver transplantation.

Work funded by educational grants from industry, paid to the Mayo Clinic, from the following companies:

  • Mallinckrodt Pharmaceuticals, for a continuing medical education symposium on hepatorenal syndrome at an American Association for the Study of Liver Diseases meeting.

Work as an author or editor for following company, with compensation as listed:

  • American College of Gastroenterology, receiving compensation as Associate Editor for American Journal of Gastroenterology.

Funding for clinical trial expenses, staff and salary support, paid to the Mayo Clinic, from the following organizations:

  • National Institutes of Health, for a trial of an oral caspase inhibitor, in subjects with decompensated non-alcoholic steatohepatitis cirrhosis.
  • National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, for a trial on treatment of acute or chronic liver failure. and treatment of decompensated cirrhosis and ascites.

Marwan S. Ghabril, MD

Marwan S. Ghabril, MDDr. Ghabril has been a transplant hepatologist for over 10 years. He is currently an Associate Professor of Medicine, and will be submitting his dossier for promotion to Professor with tenure late this year. Trained at the Mayo Clinic, Florida, he has been an integral member of the transplant team at Indiana University since 2008, and has enjoyed a busy and clinically challenging transplant practice.

His clinical experience is complemented by administrative and extensive quality work as director of an inpatient liver service. He serves on multiple multidisciplinary committees for safety, quality and utilization. Dr. Ghabril serves as a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology.

Dr. Ghabril received degree from the Royal College of Surgeons in Ireland, completed his residency at Thomas Jefferson University Hospital, and completed fellowships at Mayo Clinic.

As of September 2018, Dr. Ghabril reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Indiana University, from the following company:

  • Conatus, for a trial of emricasan in nonalcoholic steatohepatitis cirrhosis.

Maureen M. Jonas, MD

Dr. Jonas is Director of the Center for Childhood Liver Diseases at Boston Children's Hospital and Professor of Pediatrics at Harvard Medical School. She is board certified in both Pediatric Gastroenterology and Pediatric Transplant Hepatology by the American Board of Pediatrics. She is a fellow of the American Association for the Study of Liver Diseases (AASLD).

Since 1991, Dr. Jonas has been a staff physician in the Division of Pediatric Gastroenterology, Hepatology and Nutrition at Boston Children's Hospital. She was Medical Director of the Liver Transplant Program from 1991 to 2014, and Program Director for the Pediatric Transplant Hepatology Fellowship since 2010. Since 2014, she has been the Physician Quality Leader for the Pediatric Transplant Center. Prior to 1991, Dr. Jonas was in the Division of Pediatric Gastroenterology at the University of Miami Jackson Memorial Hospital, where she served as Medical Director of the Pediatric Liver Transplant Program.

She is a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology. Dr. Jonas has served on several committees of national organizations, including the Clinical Committee, the Practice Guidelines Committee and the Ethics Committee of the AASLD; the Training and Education Committee and the Executive Council of the North American Society for Pediatric Gastroenterology Hepatology and Nutrition; and the Executive Committee of the Section on Pediatrics of the American Academy of Pediatrics.

Dr. Jonas received a bachelor's degree in biology from Tufts University, and her medical degree from the University of Miami. She completed both her pediatrics residency and pediatric gastroenterology fellowship at Boston Children's Hospital.

View my board certification status via ABMS Website.

As of February 2019, Dr. Jonas reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Boston Children's Hospital, from the following companies:

  • AbbVie, providing funding for a clinical trial for treatment of hepatitis C in children.
  • Bristol-Myers Squibb, providing funding for randomized trials of entecavir for chronic hepatitis B in children.
  • Gilead Sciences, Inc., providing funding for two clinical trials of hepatitis C treatments in children.
  • Merck, providing funding for a clinical trial.

Service on data and safety monitoring boards for the following company, with honoraria:

  • Gilead Sciences, Inc., serving as the chair of a data and safety monitoring board for a clinical trial of tenofovir for chronic hepatitis B in children.

Dr. Jonas reported receiving a donation of transient elastography from Echosens for several research studies.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving annual royalties.

Andrew P. Keaveny, MD

Andrew P. Keaveny, MDDr. Keaveny is a Consultant Hepatologist in the Departments of Transplant and Internal Medicine and Medical Director of the Liver Transplant program at Mayo Clinic in Jacksonville, Florida. He is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is board certified in Gastroenterology and Transplant Hepatology.

Previously, Dr. Keaveny was a member of the Section of Gastroenterology in the Department of Medicine at Boston University Medical Center.

Dr. Keaveny is a member of the American Board of Internal Medicine Test & Policy Committee on Transplant Hepatology. He has served on several committees in the American Association for the Study of Liver Diseases and was Chair of the Education Committee from 2015 to 2017. From 2008 to 2012, he was a member of the Liver and Intestine Advisory Council of the American Society of Transplantation. He was the Program Director for the Transplant Hepatology Fellowship at Mayo Clinic Florida (MCF) from 2008 to 2013.

Dr. Keaveny has received awards for teaching from the MCF Division of Gastroenterology and Hepatology as well as the Internal Medicine Residency program. He was recognized for his contributions to the Transplant Hepatology Fellowship by receiving the Outstanding Course Director award in 2008 from the Mayo School of Continuous Professional Development.

He is on the editorial boards of Hepatology, Liver Transplantation, and Annals of Hepatology. From 2011 to 2017, he was an Associate Editor of Clinical Liver Disease. He is the author or co-author of over 60 peer-reviewed publications and edited the book, “Complications of Cirrhosis: Evaluation and Management”, published in 2015.

Dr. Keaveny received his medical degree from University College Dublin, Ireland. He completed internal medicine residencies in Dublin and Boston, and fellowships in gastroenterology and transplant hepatology at Boston University Medical Center and Lahey Clinic, respectively.

As of March 2019, Dr. Keaveny reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • Mallinckrodt, for a study to confirm the efficacy and safety of terlipressin in subjects with hepatorenal syndrome type 1, receiving funding for clinical trial expenses, staff and salary support.
  • Conatus Pharmaceuticals, for a study to assess the safety and efficacy of emricasan in subjects with decompensated non-alcoholic steatohepatitis cirrhosis, receiving funding for clinical trial expenses, staff and salary support.

Work as an author or editor for the following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.
  • Wiley-Blackwell/The American Association for the Study of Liver Disease, receiving compensation for work as an editor for Liver Transplantation.

Dr. Keaveny serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Disease, CME Subcommittee Member, without compensation.
  • American Liver Foundation, Advisory Board Member for the South-Eastern branch, without compensation.

Paul Y. Kwo, MD

Paul Y. Kwo, MDDr. Kwo is currently Professor of Medicine and Director of Hepatology at Stanford University. He is board certified in Gastroenterology and Transplant Hepatology.

Prior to joining the faculty at Stanford, he was at Indiana University for 21 years, where he served as the Medical Director of Liver Transplantation.

Dr. Kwo is a member of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology. He is also a Trustee for the American College of Gastroenterology and serves on the Clinical Research Committee for the American Association for the Study of Liver Disease. He has won multiple awards, both at the university, local and national level.

He completed his undergraduate education at Oberlin College and his medical education at Wayne State University. His internal medicine training was at University of Maryland Medical System and his gastroenterology/hepatology training was at Mayo Clinic.

As of March 2020, Dr. Kwo reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Stanford University, from the following companies:

  • Allergan, for a study to evaluate the efficacy and safety for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis, receiving funding for clinical trial expenses, staff and salary support.
  • Mallinckrodt, for a study of terlipressin in subjects with Hepatorenal Syndrome Type 1, receiving funding for clinical trial expenses, and salary support.
  • Bristol-Myers Squibb, for two trials on nonalcoholic steatohepatitis.
  • Novartis, for a study of autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy.
  • Arrowhead, for a study of liver histologic parameters in response to ARO-AAT in patients with Alpha-1 Antitrypsin Deficiency.

Dr. Kwo also received funding for clinical trial expenses, staff and salary support for a study of treatment of viremic, HBeAg-positive patients with chronic hepatitis B and for a study of treatment of iron overload in adult patients with hereditary hemochromatosis.

Attendance at investigators’ meetings, with compensation for travel expenses from the following company:

  • Arrowhead.

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Janssen.
  • Ribavirin Pregnancy Registry.

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • AbbVie, for an advisory board for hepatitis therapies.
  • Gilead, for an advisory board for nonalcoholic steatohepatitis, hepatitis B and hepatitis C therapies.
  • Mallinckrodt, for an advisory board.
  • Hepquant, for an advisory board.
  • Aligos, for an advisory board.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with honoraria:

  • Conatus, for design of clinical trials with caspase inhibitor for liver disease.
  • Edigene, for consulting on applications of novel therapeutic agents across a spectrum of liver diseases.
  • Ferring, for trial design for a study on hepatorenal syndrome.
  • Surrozen, for consulting on applications of novel therapeutic agents across a spectrum of liver diseases.
  • Ambys, for design of a clinical trial.

Work funded by educational grants from industry, paid to Stanford University, from the following companies:

  • Eisai, for HCC training, receiving salary support.

Industry-supported continuing medical education supported by the following companies, with compensation for travel expenses and honoraria:

  • Gilead, for hepatitis B/nonalcoholic fatty liver disease, receiving honoraria and reimbursement for travel expenses.
  • Mallinckrodt, for a hepatorenal syndrome symposium, paid to Medscape.

Dr. Kwo also reported receiving support from multiple companies for CME programs on complications of cirrhosis for the Chronic Liver Foundation, and for CME programs on treatment of hepatitis B and C for Scripps Health Program.

Dr. Kwo serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

Teaching in satellite symposia funded by the following company, with honoraria:

  • American College of Gastroenterology, Member of Board of Trustees, receiving reimbursement for travel expenses and honoraria.
  • American Association for the Study of Liver Diseases, Member of Clinical Research Committee, Member of Development Committee, receiving reimbursement for travel expenses and honoraria.

Cynthia Levy, MD

Cynthia Levy, MDDr. Levy is Program Director for the Transplant Hepatology Fellowship program at the University of Miami and Assistant Director of the Schiff Center for Liver Diseases. She is an Associate Professor of Medicine and is board certified in Gastroenterology and Transplant Hepatology.

Previously, Dr. Levy served as an Assistant Professor of Medicine with the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida and the Malcolm Randall VA Medical Center in Gainesville, Florida.

Dr. Levy is a member of the Steering Committee for the International Primary Sclerosing Cholangitis Study group and serves as the Chair for the TARGET-Primary Biliary Cholangitis (PBC) national registry. She currently serves as the Chair of the Clinical Research Committee for the American Association for the Study of Liver Diseases (AASLD), is a member of the Scientific Program Committee and an elected member of the Nominating Committee for the AASLD. Dr. Levy participates in the writing group for the new AASLD Practice Guidance document for PBC. Additionally, Dr. Levy is a member of the American Board of Internal Medicine Test & Policy Committee on Transplant Hepatology.

She received her medical degree from Universidade Federal do Rio de Janeiro. She completed house staff training both at her home university and subsequently at University of Miami/Jackson Memorial Hospital, in Miami, Florida. She completed her gastroenterology fellowship at Mayo Clinic in Rochester, Minnesota, and transplant hepatology fellowship at University of Florida, in Gainesville, Florida.

As of May 2019, Dr. Levy reported the following external relationships:

Preclinical research, with funding paid to the University of Miami, from the following company:

  • Pliant, for developing an anti-fibrotic medication, receiving salary support.

Funding for clinical trial expenses and staff, paid to the University of Miami, from the following companies:

  • GlaxoSmithKline, for a study for patients with primary biliary cholangitis and pruritus, receiving funding for clinical trial expenses, staff and salary support.
  • CymaBay Therapeutics, for a study with a PPAR delta agonist for primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Gilead, for two clinical trials with FXR agonist, receiving funding for clinical trial expenses, staff and salary support.
  • Novartis, for a study with FXR agonist for primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Intercept, for two studies with FXR agonist for primary biliary cirrhosis and primary sclerosing cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Eli Lilly & Company, for a study of baricitinib for primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Genkyotex, for a clinical trial of primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Enanta, for two clinical trials with FXR agonist, receiving funding for clinical trial expenses, staff and salary support, receiving funding for clinical trial expenses, staff and salary support.
  • Mitsubishi, for a clinical trial of primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • High Tide, for a clinical trial of primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.
  • Zydus, for a clinical trial of primary biliary cholangitis, receiving funding for clinical trial expenses, staff and salary support.

Attendance at investigators’ meetings, with compensation for travel expenses from the following company:

  • Gilead, for a clinical trial with FXR agonist.

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Flashlight Therapeutics, for serving on an advisory board.
  • GlaxoSmithKline, for serving on an expert panel.
  • Target PharmaSolutions, for serving as an advisor on a steering committee.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

  • Cara Therapeutics, providing consultation regarding clinical trial development for the treatment of itching in patients with liver disease.
  • Shire, providing consultation on the role of targeting G-protein-coupled receptors in cholestatic diseases.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for work as an editor.
  • American Association for the Study of Liver Diseases, Associate Editor for Liver Transplantation.

Dr. Levy serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Diseases, Member of Scientific Program Committee, without compensation.

Brendan M. McGuire MD, MS

Brendan M. McGuire, MD, MS is medical director of liver transplantation at the University of Alabama at Birmingham (UAB). After graduating from the University of Notre Dame in 1984 he completed a master's of science in bioengineering from Pennsylvania State University and a doctorate in medicine from the University of Pittsburgh in 1990. After completing his internal medicine residency and gastroenterology and hepatology fellowship at the University of Minnesota in 1996, he joined the faculty of UAB and has been there ever since. He is board certified in Gastroenterology and Hepatology and Transplant Hepatology.

Brendan McGuire has been an active volunteer within and beyond the borders of Alabama. Locally Dr. McGuire is Director of the UAB Liver Transplant Fellowship Program, a member on the Steering Committee for the UAB GI Fellowship Program, a member of the School of Medicine Promotions Committee, and a member of the Liver Transplant Evaluation Committee.

Nationally he has been an active volunteer for United Network for Organ Sharing (UNOS), American Society of Transplantation (AST) and American Association for the Study of Liver Diseases (AASLD). For UNOS, he has been on the Membership and Standards Committee, the Region 3 Liver and Intestinal Representative, a Regional Review Board Member, and a National Review Board Member. For AST, Dr. McGuire has been on the Nominating Committee, AST Practice Guidelines Committee, and has chaired the Liver and Intestinal Advisory Group. For AASLD, he has been on the Acute on Chronic Liver Failure Special Interest Group and Ethics Committee.

As of August 2019, Dr. McGuire reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Alabama-Birmingham, from the following company:

  • Gilead

Industry-supported continuing medical education supported by the following company, with compensation for travel expenses and honoraria:

  • MedIntelligence, for developing continuing medical education on thrombocytopenia.

Elizabeth Rand, MD

Dr. Rand joined the faculty of the University of Pennsylvania School of Medicine and the clinical staff of the Children's Hospital of Philadelphia in 1993 where she is now a Professor of Pediatrics and the Medical Director of the Liver Transplant Program respectively; and holds ABP American Board of Pediatrics certification in Pediatric GI as well as a Certificate of Added Qualification in Pediatric Advanced Transplant Hepatology.

Dr. Rand is involved in graduate medical education as a clinical faculty member as the Fellowship Program Director of both the Pediatric Gastroenterology (since 2000) and advanced Pediatric Hepatology (since 2010) Training Programs.

Dr. Rand is involved in graduate medical education as a clinical faculty member and also as the Fellowship Program Director of both the Pediatric Gastroenterology (since 2000) and advanced Pediatric Hepatology (since 2010) Training Programs.

Dr. Elizabeth Rand is a graduate of the University of Chicago Pritzker School of Medicine and completed her Residency in Pediatrics at the Johns Hopkins Hospital followed by Pediatric GI Fellowship at the University of Chicago.

View my board certification status via ABMS Website.

As of January 2020. Dr. Rand reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for role as section editor.
  • American Association for the Study of Liver Disease, receiving compensation for role as associate editor of Clinical Liver Disease.

Dr. Rand serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Make-A-Wish Foundation, medical advisory board member, without compensation.